{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:16:21Z","timestamp":1787022981724,"version":"build-2736575974"},"reference-count":0,"publisher":"Codon Publications","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergol Immunopathol"],"abstract":"<jats:p>Introduction: We aimed to investigate the frequency and sociodemographic and clinical distinguishing features of asthmatic patients in whom long-acting muscarinic antagonists (LAMA) were added to maintenance therapy in our clinic.\nMethods: In this cross-sectional study, data on sociodemographic, phenotypic, and clinical characteristics of patients with asthma using Steps 4 and 5 medications, who were followed up in our center for at least 1 year, were obtained from file records. Whether the patients received add-on LAMA for at least 6 months was also noted.\nResults: A total of 279 patients with asthma using Steps 4 and 5 medications (female\/male: 215\/64) with a mean age of 50.84 \u00b1 12.42 years were included in the study. Seventy-nine (28.3%) patients (female\/male: 60\/19) with a mean age of 52.45 \u00b1 11.61 years used LAMA as an add-on treatment; 28 (37.8%) at Step 4 and 51 (24.8%) at Step 5. In Steps 4 and 5, there was no difference in terms of age, sex, body mass index, smoking status, being allergic or eosinophilic, phenotype, and asthma onset between patients with and without add-on LAMA. Asthma control in the previous year was better, and minimum forced expiratory volume in 1s (FEV1) was lower in patients with LAMA than in those without in Step 4 (P = 0.001 and P = 0.030, respectively). In Step 5, the rate of being well-controlled was higher in those without add-on LAMA (P &lt; 0.001). The number of exacerbations in the previous year was higher, and minimum and maximum FEV1 were lower in patients with add-on LAMA (P &lt; 0.001 and P &lt; 0.001, respectively).\nConclusion: Our study showed that add-on LAMA treatment was effective in increasing asthma control in patients using Step 4 medication independent of baseline characteristics and asthma phenotype.<\/jats:p>","DOI":"10.15586\/aei.v52i6.1121","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:46:23Z","timestamp":1730691983000},"page":"62-71","source":"Crossref","is-referenced-by-count":1,"title":["The use of a long-acting muscarinic antagonist in the treatment of asthma: A tertiary asthma center experience"],"prefix":"10.15586","volume":"52","author":[{"given":"Bet\u00fcl","family":"\u00d6zdel \u00d6zt\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"\u00c7elebi S\u00f6zener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra \u00dcnsay","family":"Metan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Bavbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilsad","family":"Mungan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","published-online":{"date-parts":[[2024,11,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1121\/1719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1121\/1721","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1121\/1720","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/download\/1121\/1719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:46:23Z","timestamp":1730691983000},"score":1,"resource":{"primary":{"URL":"https:\/\/all-imm.com\/index.php\/aei\/article\/view\/1121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v52i6.1121","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}